Letters to the Editor
Value of anticoagulants in the treatment of pulmonary embolism From Dr D W Barritt and Dr S C Jordan Bristol Royal Infirmary, Bristol BS2 8HW Sir, We should like to comment on Dr Egermayer's critique (September Journal, p 675) of the trial that we reported in 1960. He suggests that the value of the trial was strictly limited by doubt about the diagnosis of the patients included and he misquotes the conclusions that we drew.
Of course, the diagnoses were made entirely on clinical, electrocardiographic and plain X-ray evidence because pulmonary scans were not available at that time. We did not say that symptoms suggestive of pulmonary embolism were central chest pain, haemoptysis and faintness, but that right-sided heart failure usually declared itself with faintness and central chest pain and was usually accompanied by a fall in blood pressure, a rise in jugular venous pressure and electrocardiographic changes. Under these circumstances we did place considerable reliance on the ECG pattern of acute cor pulmonale, which is so helpful in distinguishing massive pulmonary embolism from acute myocardial infarction (Braunwald 1980) . Similarly, the combination of pleuritic pain and haemoptysis is regarded by most physicians as indicating pulmonary infarction rather than pneumonia. It seems unlikely that diagnosis was incorrect sufficiently frequently to negate the main conclusion of our trial because, of the 7 patients who came to necropsy, 6 were found to have been correctly diagnosed.
It was not our conclusion that the benefits of anticoagulants relate only to the treatment of established pulmonary embolism rather than to prophylaxis against recurrence, for we recognized 5 recurrences of pulmonary embolism in the untreated group against no recurrences in the treated group. We did, however, think it likely that anticoagulant therapy also reduced the risk of death from heart failure or from pulmonary infarction by discouraging further deposition of thrombus in the pulmonary arteries where the blood flow is severly impeded. We were well aware at that time that heparin did not possess a thrombolitic action.
. All our subsequent experience leads us to believe that our conclusion was correct -that in a patient who has already had pulmonary embolism the subsequent course of the disease is affected by anticoagulant therapy and that the mortality of pulmonary embolism is thereby reduced. 
Aetiology of gynaecological cancer From Dr S N Jarvis Registrar in Community Medicine Northumberland Area Health Authority
Dear Sir, May I suggest that in Figure 2 of Mr Geoffrey Chamberlain's paper (April Journal, p 246) the 'registrations ofcarcinoma of the cervix' are not the same thing as the 'incidence' as implied in the text.
If all cases of carcinoma-in-situ found were registered, this would still only represent the prevalence in a selected population. The peak incidence of carcinoma-in-situ (cervix), in the sense of new cases appearing in a previously normal representative population of women, is reported to be at age 25 to 29 years (Walton 1976) , that is some 10 years earlier than shown in Figure  2 .
With regard to invasive carcinoma of the cervix, registrations present a misleading picture of incidence unless related to the population of women at risk. Such age-specific rates show a later peak or plateau at about 60 +. A copy of this letter was sent to Mr Chamberlain, whose reply follows: Dear Sir, I thank Dr Jarvis for the courtesy of sending me a copy of his letter. He is correct in his comment that the term incidence should not be used in reference to Figure 2 of my paper which gives the number of registrations, the numerator
